{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:28:45Z","timestamp":1773894525176,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejca.2025.116148","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T16:34:01Z","timestamp":1764779641000},"page":"116148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Subsequent anticancer therapy in patients randomized to placebo alone or best supportive care"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5798-6742","authenticated-orcid":false,"given":"Christopher","family":"Rios","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-3978","authenticated-orcid":false,"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timoth\u00e9e","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116148_bib1","unstructured":"WMA - The World Medical Association-WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Participants. Accessed 2025. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/."},{"issue":"2","key":"10.1016\/j.ejca.2025.116148_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0895-4356(99)00139-0","article-title":"de Craen AJ. Why use placebos in clinical trials? A narrative review of the methodological literature","volume":"53","author":"Vickers","year":"2000","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.ejca.2025.116148_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.ejca.2025.116148_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular Carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116148_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2011.38.7571","article-title":"Progression-free survival: meaningful or simply measurable?","author":"Booth","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.116148_bib6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1470-2045(22)00015-8","article-title":"Progression-free survival: it is time for a new name","volume":"23","author":"Gyawali","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116148_bib7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"issue":"8","key":"10.1016\/j.ejca.2025.116148_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7190","article-title":"An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023)","volume":"13","author":"Elbaz","year":"2024","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.ejca.2025.116148_bib9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrclinonc.2017.72","article-title":"Combining drugs and extending treatment - a PFS end point is not sufficient","volume":"14","author":"Gyawali","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116148_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jnci\/95.1.19","article-title":"Placebo effects in oncology","volume":"95","author":"Chvetzoff","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ejca.2025.116148_bib11","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/annonc\/mdy116","article-title":"When is crossover desirable in cancer drug trials and when is it problematic?","volume":"29","author":"Haslam","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2025.116148_bib12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the us food and drug administration","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.116148_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.008","article-title":"Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study","author":"Rossi","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116148_bib14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejca.2022.06.023","article-title":"Dose modification rules and availability of growth factor support: a cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021","volume":"172","author":"Olivier","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.116148_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44770","article-title":"Reporting of physicians\u2019 or investigators\u2019 choice of treatment in oncology randomized clinical trials","volume":"5","author":"Olivier","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"24","key":"10.1016\/j.ejca.2025.116148_bib16","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.22.02675","article-title":"Ensuring ethical postprogression therapy for patients in randomized trial control arms","volume":"41","author":"Cliff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116148_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjonc-2024-000322","article-title":"Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials","volume":"3","author":"Sherry","year":"2024","journal-title":"bmjonc"},{"key":"10.1016\/j.ejca.2025.116148_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2024.1569","article-title":"Postrecurrence treatment in neoadjuvant or adjuvant fda registration trials: a systematic review","author":"Olivier","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116148_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1186\/s12885-023-10917-z","article-title":"Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020","volume":"23","author":"Olivier","year":"2023","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2025.116148_bib20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.116148_bib21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.116148_bib22","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2025.116148_bib23","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/bjc.2016.309","article-title":"A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer","volume":"115","author":"Kim","year":"2016","journal-title":"Br J Cancer"},{"issue":"9940","key":"10.1016\/j.ejca.2025.116148_bib24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2025.116148_bib25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2025.116148_bib26","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"issue":"10395","key":"10.1016\/j.ejca.2025.116148_bib27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ejca.2025.116148_bib28","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ejca.2025.116148_bib29","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/bjc.2016.309","article-title":"A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer","volume":"115","author":"Kim","year":"2016","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.ejca.2025.116148_bib30","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"9911","key":"10.1016\/j.ejca.2025.116148_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2025.116148_bib32","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann Oncol"},{"issue":"9863","key":"10.1016\/j.ejca.2025.116148_bib33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"9829","key":"10.1016\/j.ejca.2025.116148_bib34","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ejca.2025.116148_bib35","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased SUrvival with Enzalutamide in Prostate Cancer after Chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"New Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:05:53Z","timestamp":1773885953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925010342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"alternative-id":["S0959804925010342"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116148","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subsequent anticancer therapy in patients randomized to placebo alone or best supportive care","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116148"}}